Combination of Proteomedix and Blue Water Biotech to form Onconetix

20 December 2023

Proteomedix AG, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech, Inc. (Nasdaq: BWV) are forming together a company called Onconetix, Inc. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial products are Entadfi®, an FDA-approved, once-daily oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), and Proclarix®, a European CE IVD approval for prostate diagnostics and a lab developed test (LDT) currently in the U.S., originally developed by Proteomedix.

VISCHER is advising Proteomedix on all Swiss law matters of the transaction with a team consisting of Matthias Staehelin, Timothy Woodtli and Benjamin Sarasin (all Corporate/M&A).

Authors: Dr. Matthias Staehelin, Timothy Woodtli and Benjamin Sarasin